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■ Abstract
Background: There are no previous Spanish guidelines or consensus statements on bradykinin-induced angioedema.
Aim: To draft a consensus statement on the management and treatment of angioedema mediated by bradykinin in light of currently available 
scientifi c evidence and the experience of experts. This statement will serve as a guideline to health professionals.
Methods: The consensus was led by the Spanish Study Group on Bradykinin-Induced Angioedema, a working group of the Spanish Society 
of Allergology and Clinical Immunology. A review was conducted of scientifi c papers on different types of bradykinin-induced angioedema 
(hereditary and acquired angioedema due to C1 inhibitor defi ciency, hereditary angioedema related to estrogens, angioedema induced by 
angiotensin-converting enzyme inhibitors). Several discussion meetings were held to reach the consensus.
Results: Treatment approaches are discussed, and the consensus reached is described. Specifi c situations are addressed, namely, pregnancy, 
contraception, travelling, blood donation, and organ transplantation.
Conclusions: A review of and consensus on treatment of bradykinin-induced angioedema is presented.
Key words: Angioedema. C1-inhibitor. Bradykinin. Estrogens. ACE inhibitors.
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Introduction
This is the second in a series of 
2 papers that describe the consensus 
reached on the management and 
treatment of angioedema (AE) induced 
by bradykinin (BK).
Epidemiology, classification, 
genetics, pathophysiology, clinical 
symptoms, and diagnosis are addressed 
in Part 1 [1]. Part II addresses treatment, 
follow-up, and special situations.
A summary of the classifi cation and 
nomenclature of the different types of 
bradykinin-induced angioedema (BK-
AE) can be seen in Table 1.
■ Resumen
Introducción: No existen guías previas españolas sobre el manejo del angioedema mediado por bradicinina.
Objetivos: Alcanzar un consenso sobre el manejo y tratamiento del angioedema mediado por bradicinina a la luz de la evidencia científi ca 
disponible y la experiencia de los expertos, que sirva como guía para los profesionales de la salud.
Métodos: SGBA/GEAB, un grupo de trabajo de la SEAIC dirigió el consenso. Se realizó una revisión de los documentos científi cos publicados 
sobre los diferentes tipos de angioedema mediado por bradicinina [angioedema hereditario o adquirido por defi ciencia de inhibidor de la 
C1 esterasa, angioedema hereditario relacionado con estrógenos (AEH tipo III, AEH-FXII), angioedema inducido por IECA (inhibidores del 
enzima convertidor de angiotensina]. Hubo varias reuniones del SGBA/GEAB para alcanzar el consenso.
Resultados: Se revisan y discuten los diferentes tratamientos disponibles y se describe el consenso alcanzado. Se abordan situaciones 
específi cas (embarazo, anticoncepción, viajes, hemodonación, trasplante de órganos).
Conclusiones: Se presenta una revisión del tratamiento del angioedema mediado por bradicinina y un consenso sobre su tratamiento en 
España. 
Palabras clave: Angioedema. C1 inhibidor. Bradicinina. Estrógenos. Inhibidores de la ECA.
Abbreviations: AE, angioedema; ACEi, angiotensin-converting enzyme inhibitors; C1-INH, C1 esterase 
inhibitor.
Table 1. Classifi cation of Bradykinin-Induced Angioedema
  
 With C1-INH  defi ciency  Type I (HAE-C1-INH  
    type I)   
  
Hereditary
 Type II (HAE-C1-INH
   type II)
Bradykinin-  Acquired (AAE-C1-INH)
induced AE
 With normal C1-INH Hereditary (estrogen- With F12 mutation
  related) (HAE-FXII)
  (HAE type III) Without F12 mutation
   (HAE-unknown)
  Associated with ACEi (AE-ACEi) 
Methods
The methodology is described in Part I [1].
Treatment
A schematic approach to treatment is shown in Table 2.
A. Hereditary Angioedema With C1 Esterase Inhibitor
     Defi ciency (HAE-C1-INH Types I and II)
1. Secondary prevention 
1.1 Avoid precipitating factors
Early identifi cation of precipitating factors is important 
(see Table 3).
1.1.1. Infectious processes: If infectious bacterial foci 
are detected (oral, sinus, respiratory, or digestive), antibiotic 
treatment (or surgery, if necessary) should be initiated.
In frequently recurring attacks that are mainly, but not 
exclusively, located in the abdomen, Helicobacter pylori 
infection should be investigated and eradication therapy should 
be administered if detected [2-4].
1.1.2. Trauma: It is advisable to avoid trauma, especially 
in dental operations and in those medical and surgical 
interventions that carry a risk for AE (see short-term 
prophylaxis).
1.1.3. Mental stress: Situations of mental stress should be 
identifi ed and the need for psychotherapy or psychoactive drug 
treatment evaluated [5,6].
1.1.4. Drugs: Drugs that can increase the frequency and 
severity of AE attacks (Table 3) should be avoided.
1.1.4.1 Angiotensin-converting enzyme inhibitors (ACEi): 
ACEi should be strictly avoided [7,8].
1.1.4.2. Angiotensin II receptor blockers (ARB): ARBs 
have not been shown to trigger AE episodes in patients with 
HAE-C1-INH and can be used with care [7].
1.1.4.3. Estrogens: Estrogens must be avoided in 
oral contraceptives, hormone replacement therapy, and 
estrogenically active drugs [8,9].
1.2 Vaccination recommendations
1.2.1. Vaccination against hepatitis B virus is recommended 
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Table 2. Schematic Approach to Treatment
  
A. Hereditary angioedema with C1 esterase inhibitor 
defi ciency or dysfunction
 1. Secondary prevention
  1.1. Avoidance of precipitating factors
   1.1.1. Infectious processes
   1.1.2. Trauma
   1.1.3. Mental stress
   1.1.4. Drugs 
    1.1.4.1. Angiotensin-converting enzyme
                 inhibitors
    1.1.4.2. Angiotensin receptor blockers
    1.1.4.3. Estrogens
  1.2. Vaccination recommendations
   1.2.1. Hepatitis B virus vaccination
 2. Drug treatment and support
  2.1. Treatment for angioedema episode or acute attack
   2.1.1. Plasma-derived C1 esterase inhibitor
            concentrate
   2.1.2. Icatibant acetate
   2.1.3. Other drugs
    2.1.3.1. Ecallantide
    2.1.3.2. Fresh frozen plasma
    2.1.3.3. Intravenous tranexamic acid
    2.1.4. Support treatment 
    2.1.5.  Other medicines under development:   
   recombinant human C1-INH (rhC1INH)
     (Ruconest)
  2.2. Maintenance therapy or long-term prophylaxis
   2.2.1. Attenuated androgens: danazol, stanozolol,
             oxalandrone
   2.2.2. Antifi brinolytic agents
    2.2.2.1. Epsilon-aminocaproic acid
    2.2.2.2. Tranexamic acid
   2.2.3. Plasma-derived C1 esterase inhibitor
             concentrate
  2.3. Short-term prophylaxis
   2.3.1. Plasma-derived C1 esterase inhibitor
    concentrate
   2.3.2. Fresh frozen plasma
   2.3.3. Attenuated androgens
   2.3.4. Antifi brinolytic agents
   2.3.5. Icatibant acetate
   2.3.6. Ecallantide
  2.4. Peculiarities of treatment in children and
   adolescents
   2.4.1. Treatment of acute episodes
   2.4.2. Long-term prophylaxis
   2.4.3. Short-term prophylaxis
   2.4.4. Educating patients and their families
B. Acquired angioedema with C1 esterase inhibitor 
defi ciency
C. Hereditary angioedema related to estrogens, including 
hereditary angioedema associated with a mutation in F12 
 1. Secondary prevention: withdrawal of exogenous
     estrogens
 2. Drug treatment
  2.1. Treatment of acute attack  
  2.2. Maintenance therapy or long-term prophylaxis
  2.3. Short-term prophylaxis
D. Angioedema induced by angiotensin-converting enzyme 
inhibitors
Table 3. Trigger Factors of Acute Edema in Patients With HAE-C1-INH
  
 Psychological Emotional stress, anxiety
 Trauma Especially important are those affecting the
 (even minimal) oral cavity (dental manipulations,
  gastroscopy, bronchoscopy, orotracheal
   intubation)
 Hormonal Menses, pregnancy, and puberty
 Drugs Estrogen-containing drugs (oral   
  contraceptives, hormonal replacement
  therapy) and ACEi
 Infections Upper respiratory track infections,   
  Helicobacter pylori infection
Abbreviations: ACEi, angiotensin-converting enzyme inhibitors; HAE-
C1-INH, hereditary angioedema with C1 esterase inhibitor defi ciency.
for nonimmunized patients when the diagnosis for the disease 
is made, since these patients might have to receive plasma 
derivatives [9,10].
2. Drug treatment and support 
Treatment is usually considered at 3 different levels [8]:
2.1. Treatment of acute AE attacks 
2.2. Maintenance therapy (long-term prophylaxis)
2.3. Short-term prophylaxis 
2.1 Treatment of an acute AE episode
It is important not to delay the administration of treatment, 
especially if the location of the attack is life-threatening 
[11,12].
Indications for treatment of acute episodes depend on the 
severity and location of the AE episodes. One should treat 
all episodes of glottic edema and also those that affect the 
cervicofacial or pharyngolaryngeal region, as well as most 
abdominal episodes. Peripheral episodes should be treated 
based on the impact on the patient’s quality of life (Table 4).
Table 4. Indications for Long-term Prophylaxis, Short-term Prophylaxis 
and Symptomatic Treatment of Acute Edema Attacks
  
  Indication
 Acute treatment Edema of the glottis
  Pharyngolaryngeal edema
  Cervicofacial edema
  Abdominal edema
  Moderate to severe peripheral edema
 Long-term  Edema of the glottis
 prophylaxis  More than 1 edema episode per month
 (maintenance More than 1 severe abdominal attack 
 treatment) More than 1 severe cervicofacial attack 
  Altered quality of life 
 Short-term Odontological manipulations 
 prophylaxis Endoscopy, bronchoscopy 
  Surgical wound infection
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It is important to point out that this type of edema, which 
is triggered by an increase in BK levels, does not respond to 
therapy with antihistamines, corticosteroids, or adrenaline 
[8,13]. 
2.1.1. Plasma-derived C1 esterase inhibitor concentrate 
(pdhC1INH) (C1 esterase inhibitor replenishment or 
replacement therapy): pdhC1INH has proven effective in 
the resolution of acute AE attacks, both in uncontrolled 
studies of large series of patients and in placebo-controlled 
randomized clinical trials [11,14-22]. It comes in several 
pharmaceutical presentations: Berinert (CSL-Behring GmbH, 
Marburg, Germany), Cetor/Cebitor (Sanquin, Amsterdam, 
The Netherlands), and Cinryze (Viropharma Inc, Exton, 
Pennsylvania, USA) (see Table 5 for a comparison of available 
and investigational new drugs for acute treatment).
For more than 20 years, Berinert-P (CSL-Behring GmbH) 
has been available in Spain through the “Medicamentos 
Extranjeros” (Foreign Medications) office. Berinert-P is 
a purifi ed and pasteurized pdhC1INH [23,24], which has 
an excellent postlaunch record for effectiveness and safety 
[23,24]. It was fi nally marketed in Spain in August 2009 
as Berinert lyophilized in 500-U vials for intravenous 
administration. It can be preserved at 2ºC-25ºC [25]. 
The manufacturing process of another C1-esterase inhibitor 
formulation, Cinryze, has incorporated a nanofi ltration step 
through 2 serial 15-nm filters to reduce transmission of 
enveloped and nonenveloped viruses and possible prions 
[22,26].
Dose: We recommend an intravenous dose of 20 U/kg, 
which proved effective in the IMPACT1 study [21]. Before 
randomized controlled clinical trials were conducted, the 
dose varied with body weight, according to an international 
agreement [7]. The drug should be administered intravenously, 
as follows: patients weighing ≤50 kg, 500 U; patients weighing 
50-100 kg, 1000 U; and patients weighing >100 kg, 1500 U 
[7]. The dose may be repeated if there has been no response 
or if the response is incomplete, usually after 1 hour. It begins 
to act around 30 minutes after injection, and its effect lasts 2 
to 4 days [7,8,11,27]. 
In some case series, the doses that led to improvement 
were lower [11,17-20]. 
Possible side effects: pdhC1INH is purifi ed from human 
plasma; therefore, there is a theoretical risk of transmission of 
infectious agents. However, the safety of the products currently 
available on the market (Berinert, Cetor, Cebitor, Cinryze) is 
ensured by a series of protective measures, and there have 
been no demonstrated cases of viral transmission [8,18-24,28].
A procoagulant effect has been reported with doses above 
200 U/kg [29,30], which are much higher than those used for 
HAE-C1-INH [21]. However, these effects have not been 
observed when pdhC1INH is used at recommended doses in 
patients with HAE-C1-INH or acquired angioedema (AAE-C1-
INH) or in studies conducted with doses of 100 U/kg in infants 
operated on to correct transposition of the great arteries [31,32].
2.1.2. Icatibant acetate (HOE-140, JE-049) (BK type 
2 receptor blocker) (Firazyr, Jerini AG, Berlin, Germany): 
Icatibant acetate is a synthetic decapeptide, a highly specifi c 
second-generation antagonist of the BK B2 receptor (B2R), 
which inhibits the vasodilation produced by BK [33-35]. Its 
effectiveness has been shown in clinical trials [33,36-38] and 
in patient series [39]. No serious adverse reactions have been 
reported, the only signifi cant side effect being injection site 
reactions (in more than 95% of cases) consisting of self-limiting 
erythema, edema, pruritus, and pain [33,36-38]. Icatibant 
acetate has recently been approved by the European Medicines 
Agency (EMA), which granted marketing authorization in July 
2008 [40], and has been available in Spain since March 2009.
There is no information about its effi cacy and safety profi le 
in patients younger than 18 years or in women who are pregnant 
or breastfeeding. It should not be used in patients with active 
ischemic heart disease or those who have had ischemic stroke 
in the preceding 2 weeks [41].
Icatibant acetate comes in prefi lled syringes with the dose 
that should be administered subcutaneously (30 mg in 3 mL). 
It is stored at room temperature (2ºC-25ºC). Currently, it is 
only approved for symptomatic treatment of acute AE attacks 
in adult patients with HAE-C1-INH. If an adequate response 
does not occur, re-injection is indicated after 6 hours have 
elapsed. In 85%-92% of cases, 1 dose is suffi cient, in 7%-12% 
of cases a second dose is necessary, and in 1%-3% a third dose 
is required [37,38]. The administration of more than 3 doses 
within a 24-hour period or more than 8 doses in 1 month is 
not recommended [41].
It is essential that patients have medication (eg, pdhC1INH 
[Berinert], icatibant acetate, or any other approved drug) 
available at all times, so that emergencies can be managed 
quickly and effectively at home or at a health center. In this 
way, autonomy and quality of life are increased [10,42,43].
In cases of frequent or more severe AE episodes, training 
programs can be given for self-administration of intravenous 
pdhC1INH [8,42-45]. In the case of icatibant acetate, 
subcutaneous administration may facilitate self-administration 
(authorized by the EMA in March 2011).
2.1.3. Other drugs
2.1.3.1. Ecallantide (DX-88, EPI-KAL-2)(Kalbitor)(Dyax 
Corp, Cambridge, Massachusetts, USA)
Ecallantide is a very potent, reversible, and highly 
specifi c human plasma kallikrein inhibitor, whose half-life is 
2.0±0.5 hours [46]. Its effectiveness has been demonstrated 
in various clinical trials [46-50]. Anaphylactic reactions have 
been reported [51,52], as have other acute allergic reactions 
[53]. The United States Food and Drug Administration 
approved its use in December 2009 for treatment of acute AE 
episodes in patients aged 16 years and older. It is administered 
subcutaneously at 30 mg (divided into 3 doses). This drug 
should be stored refrigerated [54].
2.1.3.2. Fresh frozen plasma
In countries where pdhC1INH, icatibant, and ecallantide 
are not available, fresh frozen plasma (FFP) can be used 
instead, as long as it undergoes viral inactivation, preferably 
with solvents and detergents [5,55-60]. FFP works by 
supplying C1-INH. Although a theoretical risk of aggravating 
AE symptoms exists, because, in addition to C1-INH, FFP 
also supplies substrates (FXII, prekallikrein, high-molecular-
weight kininogen), which can in turn lead to an increase in 
BK levels before the C1-INH can act [55,56,60-62], there are 
no scientifi c data linking exacerbation of the disease with this 
treatment [55].
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The dosage has not been studied and is generally the same 
as that used in coagulation disorders: 2 units of 200 mL each [7]. 
Possible side effects include alloimmunization, 
anaphylactic or allergic reactions, transmission of infectious 
diseases (viruses, Creutzfeldt-Jakob disease), and excessive 
intravascular volume with risk of hypervolemia and heart 
failure [62].
2.1.3.3. Tranexamic acid
Tranexamic acid (Amchafibrin, Rottapharm Madaus, 
Milan, Italy) competitively inhibits activation of plasminogen, 
which, under normal conditions, is inhibited by C1-INH, 
thus reducing the conversion of plasminogen to plasmin 
(fi brinolysis) [63]. In patients with HAE-C1-INH, this could 
prevent the development of AE attacks by inhibiting the 
activation of the fi rst component of the complement induced 
by plasmin [8].
There are no data based on controlled clinical trials. High 
intravenous or oral doses have been used (15 mg/kg every 4 
hours), although this has only proven effective in prodromal 
phases of the attack [7,64].
2.1.4. Support treatment 
Associated symptoms such as pain, nausea and/or 
vomiting, or hypotension symptoms caused by third-space 
phenomena (in abdominal attacks) should receive symptomatic 
treatment with analgesics, antispasmodics, antiemetics, and 
fl uid replacement [8,65].
The angioedema attack should be closely monitored, 
especially in pharyngolaryngeal episodes, until stable 
remission of signs and symptoms has been verified. If 
necessary, the patient should be referred to the intensive care 
unit [65], since intubation or tracheotomy could become 
necessary at any time [67]. 
2.1.5. Other medicines under development: Recombinant 
human C1-INH (rhC1INH) (Ruconest, Pharming Technologies 
BV, Leiden, The Netherlands).
This rhC1INH is produced in transgenic rabbits in which the 
human C1NH gene has been inserted. rhC1INH is excreted in 
milk, which is then purifi ed. It has the advantages of being a C1-
INH replacement therapy without the risk of transmitting blood-
There are no studies comparing the effi cacy, safety, and 
tolerance of pdhC1INH, icatibant acetate, ecallantide, and 
rhC1INH. 
2.2. Maintenance therapy or long-term prophylaxis
This kind of treatment aims to reduce the frequency, 
severity, and length of acute AE crises [8,65,78]. The goal of 
treatment is to reduce the number and severity of AE attacks 
to 2 or fewer minor episodes a year [79].
Indications for establishing long-term prophylaxis are 
shown in Table 4 and vary depending on patient access to 
adequate acute treatment [8-10,66,78,80,81].
Attenuated androgens (AA) are much more effective 
than antifi brinolytic agents (AF) (97% vs 28%) [78] and are 
the treatment of choice [7,8,27,78], except when there are 
contraindications (Table 6) [82].
The drugs and doses for long-term prophylaxis are 
summarized in Table 7.
Table 6. Contraindications for the Use of Attenuated Androgens
  
 – Children
 – Pregnant women
 – Breast cancer
 – Prostate carcinoma
 – Nephrotic syndrome
 – Signifi cant alterations of hepatic function
Table 7. Long-term Prophylaxis: Drugs and Doses
 
 Pharmacological Group Drug Doses in Adults Doses in Children 
  Danazol Induction: 400 mg/d 2.5 mg/kg/d
    600 mg/d
    Maintenance:
    100 mg/48-72 h
Attenuated androgens Stanozolol Induction: 6-12 mg/d
    Maintenance:
    2 mg/72 h 
  Oxandrolone 0.1 mg/kg 
  EACA 1 g/6-8 h  0.17-0.43 g/kg/dAntifi brinolytics
 Traneamic acid 1000-3000 mg/d 20-40 mg/kg/d
C1-INH replacement pdhC1INH 1000-1500 U 20 U/kg/1-3
    1-3 times a week times a week
borne human infections and is suitable for 
large-scale production. The active substance 
is called Conestat alfa, which has proven 
effective in the treatment of acute AE attacks 
[68-74]. It can be kept at room temperature, 
although it should be refrigerated during 
summer. It is administered intravenously 
and the doses used in clinical trials range 
from 50 U/kg to 100 U/kg [73]. The 50-U/kg 
dose was approved by the EMA in October 
2010 [75].
Recombinant products are potentially 
immunogenic and carry a risk of producing 
neutralizing antibodies, allergic reactions, 
or both [76,77]. Data on immunological 
safety are encouraging, with no antibody 
production and no adverse immunological 
effects observed, except for an anaphylactic 
reaction in 1 patient with undisclosed rabbit 
allergy [76].
2.2.1. Attenuated androgens 
17-α-Alkylated synthetic derivatives (danazol, stanozolol) 
are very effective and have fewer associated side effects than 
other androgens [79,83,84]. 
The mechanism of action of AAs in HAE-C1-INH is 
not clear, although various effects may contribute to their 
effectiveness, for example, a significant increase in C1-
INH plasma levels with high doses [84], an increase in the 
expression of C1-INH mRNA in mononuclear cells with 
the minimum effective dose [85], and an increase in plasma 
Abbreviation: C1-INH, C1 esterase inhibitor; EACA, ε-aminocaproic acid.
Spanish Consensus on Bradykinin-Induced Angioedema (II)
 J Investig Allergol Clin Immunol 2011; Vol. 21(6): 422-441© 2011 Esmon Publicidad
428
levels of aminopeptidase P, an enzyme that participates in the 
catabolism of kinins [86].
Danazol is a potent gonadotropic inhibitor with partial 
antigestagenic, anabolic, and androgenic activity [84,87,88]. 
An initial induction dose (400-600 mg/day) is given until 
the patient is asymptomatic. It is then slowly reduced to the 
minimal effective maintenance dose, which can be as low as 
50-100 mg every other day [5,7,8,27]. An alternative consists 
of starting with low doses of danazol and increasing them as 
needed [7,27,89].
Stanozolol is an anabolic steroid with certain anticoagulant 
properties [90]. An initial induction dose (6 mg/day in 3 doses) 
is prescribed until the patient is asymptomatic, with subsequent 
reductions every 2 months, depending on symptom severity, 
until the minimal effective maintenance dose is reached (which 
may be as low as 2 mg twice a week) [91,92].
Stanozolol has been shown to be more effective than 
danazol, with a lower frequency of side effects (menstrual 
irregularities and weight gain) [79].
Oxandrolone has also been used, although to a lesser extent 
[93]. It is not available in Spain, but it is available elsewhere 
(eg, USA, Brazil). The dosage used is 0.1 mg/kg (2.5 to 20 
mg/day), taken in 2 to 4 doses [94-97].
The goal is to reach the lowest effective dose that controls 
symptoms without the need to normalize C4 or C1-INH levels. 
Alternate-day or rotating schedules can be used to reduce side 
effects [84].
Concentrated attacks are common during menstruation 
[98,99]; therefore, doubling the dose of AA during menstruation 
may be useful [100].
Doubling the AA dose for 3-7 days is also recommended 
when patients present infections or if a prodrome is noted [7].
The main side effects are disorders of libido, impotence, 
weight gain, menstrual irregularities, breast atrophy/
hypotrophy, acne, voice changes, increased atherogenic index, 
Table 8. Secondary Effects of Attenuated Androgens
 
 Residual Seborrhea
 hormonal Acne
 activity Hirsutism
  Voice deepening
  Decrease in breast size
  Vasomotor symptoms
  Menstrual irregularities (amenorrhea,
  oligomenorrhea, menorrhagia)
  Decreased libido
  Virilization of fetus, children, and women
  Increase in body weight
 Alkylation in Hepatotoxicity: necrosis, hepatic peliosis,  
 17-α position cholestasis, hepatocellular neoplasm
 Other Lipoprotein alterations: increased risk of  
  atherogenesis 
  Increased creatine phosphokinase
  Arterial hypertension
  Premature closure of epiphyseal plates:   
  decreased growth rate
  Increased hematocrit
polycythemia, hypertension, hematuria, transient increases 
in transaminases, hepatic necrosis, cholestatic hepatitis, 
hepatosplenic peliosis, transient increases in muscle enzymes 
(creatine phosphokinase and aldolase), and rhabdomyolysis 
[82] (Table 8). There have also been documented cases of 
hepatic adenoma in patients who received danazol in doses 
greater than 200 mg/day for more than 10 years [101-105] 
and adenocarcinoma [106].
An increased risk of early atherosclerosis has been 
reported in patients with HAE-C1-INH treated with danazol 
when compared to those not treated with danazol and 
healthy subjects. In addition, serum high-density lipoprotein 
cholesterol and apolipoprotein A-I are decreased and low-
density lipoprotein cholesterol and apolipoprotein B-100 
increased [89]. However, a subsequent study did not fi nd 
differences between patients who were treated with danazol 
and those who were not [107].
The risk of rhabdomyolysis is increased after 
coadministration of danazol and high doses of statins [108-
111].
2.2.2. Antifi brinolytic agents 
2.2.2.1. ε-Aminocaproic acid 
ε-Aminocaproic acid (EACA) is effective in preventing 
AE attacks [112-114]. Generally, the dose used is 1 g every 
6-8 hours [115], although this can be increased to 12 g/day 
divided into 4 doses [8].
The main side effects are thrombosis, extensive muscle 
necrosis, and, more frequently, transient increases in creatine 
phosphokinase and aldolase associated with muscle pain, 
weakness, and fatigue [113,114].
EACA is less effective than tranexamic acid and can cause 
muscle necrosis.
2.2.2.2. Tranexamic acid
Tranexamic acid is a cyclic derivative of EACA and has 
proven effective in preventing AE attacks [64,116].
The dose is 1000-3000 mg/day (divided into 3-4 doses).
 Possible side effects include muscle cramps, nausea, 
diarrhea, hypotension, dizziness, and fatigue [64,116] (Table 9). 
Retinal and liver disorders have been reported in laboratory 
animals; therefore, periodic funduscopy is recommended [64].
AFs should be discontinued before surgery, as they may 
theoretically promote thromboembolic events [117].
2.2.3. Human plasma–derived C1 esterase inhibitor 
concentrate (pdhC1INH)
Regular administration of intravenous pdhC1INH at 
different intervals may prevent the development of acute 
Table 9. Side Effects of Antifi brinolytics
  
 – Muscle necrosis: asthenia, myalgia, increase in CPK and
     aldolase
 – Dizziness, postural hypotension
 –  Nausea, diarrhea, abdominal pain
 –  Muscle cramps
 –  Dysmenorrhea
 – Pruritus
 –  Thrombosis
Abbreviation: CPK, creatine phosphokinase.
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AE attacks [15,22,44,118,119]. The FDA approved Cinryze 
in October 2008 for prophylactic or long-term treatment 
of adolescent patients (older than 9 years) and adults. The 
effective dose was 1000 U twice a week [22]. However, dose 
and frequency must be adjusted on an individual basis, between 
500 and 1000 U from once to 3 times a week.
pdhC1INH is indicated for severe attacks that occur despite 
prophylactic treatment with high doses of AAs or when it 
is necessary to discontinue AAs due to their side effects or 
contraindications [8,42,44,118,119].
The arguments against its use include the risk of developing 
allergic reactions, the risk of transmitting new infectious 
diseases, and the possibility of diminished effectiveness if 
administered on a continuous and prolonged basis [119,120].
Some European centers have developed training programs 
to teach patients intravenous self-administration of this drug 
[8,42-45].
2.3. Short-term prophylaxis
Short-term prophylaxis is indicated for patients who 
undergo surgical or medical procedures that may involve trauma 
to the cervicofacial region with a risk of laryngeal edema. 
These procedures include dental operations, tonsillectomy, 
maxillofacial surgery, digestive endoscopy, bronchoscopy, and 
surgical interventions that require intubation [8,27,78,121]. 
Short-term prophylaxis may also be indicated during surgery 
to prevent local edema from altering the surgeon’s work area 
and affecting the outcome of surgery. 
During surgery, it is advisable, whenever possible, to use 
regional anesthetic techniques to avoid trauma resulting from 
oropharyngeal intubation [8,27,122].
The information available in the international literature 
is limited to case reports and small series. Moreover, as not 
Table 10. Short-term Prophylaxis
 
 Pharmacological Group Drug Adults Children 
C1-INH replacement pdhC1INH 500-1500 U 20 U/kg 1 h before
   1-4 h before the event the event
  Fresh frozen 2 U (400 mL) 1 h 10 mL/kg 1 h
  plasma before the procedure before procedure
  Danazol 400-600 mg/24 h for 10 mg/kg/d for
   5-7 d before the event 5-7 d before to
   and 2-3 d after the 2-3 d after the
Attenuated androgens  event event
  Stanozolol 4-6 mg/24 h for 5 d 
   before the event and 
   3 d after the event
Antifi brinolytics Tranexamic 1 g/6 h for 5 d before 500 mg/6 h for 2 d
(seldom used) acid the event and 2 d after before the event
   the event and 2 d after the
    event
   
all patients develop AE attacks after 
surgery, it is difficult to assess the 
effectiveness of premedication in 
small series.
Short-term prophylactic treatment 
was successful using AAs [123], 
AFs (EACA [124], tranexamic acid 
[125,126]), FFP [127], and pdhC1INH 
[128,129]). Although there are no 
effi cacy data for pdhC1INH compared 
to other treatments, pdhC1INH is the 
treatment of choice in countries where 
it is available, especially if intubation is 
required or surgery is major [7,8,9,27].
The risk of developing secondary 
AE attacks due to dental or oral 
operations and to surgical interventions 
cannot be completely avoided with 
preoperative prophylaxis [130-132]; 
therefore, acute treatment should 
always be available and the patient 
should be monitored after surgery. 
In addition, the patient should be 
informed about the possibility of 
developing edema, with instructions 
on what to do should the case arise. 
Drugs and doses for short-term prophylaxis are shown in 
Table 10. 
2.3.1. Human plasma-derived C1 inhibitor concentrate
The dose is 500 to 1000 U (<50 kg, >50 kg) 1 to 4 hours 
before surgery. The effect lasts 2 to 4 days. A second dose of 
pdhC1INH should be on hand throughout the operation.
2.3.2 Fresh frozen plasma
If pdhC1INH is not available (as is still the case in some 
countries), 2 units of FFP (treated with detergents) can be 
administered 1 hour before the procedure [9]. 
2.3.3. Attenuated androgens 
AAs take about 5 days to produce an effect; therefore, they 
cannot be used in emergency situations.
Danazol (Danatrol, Sanofi -Aventis) can be administered at 
a dose of 400-600 mg/day, 5-7 days before and up to 2-3 days 
after the intervention. Stanozolol (Winstrol, Desma Laboratorio 
Farmacéutico SL, Madrid, Spain) can be administered at a dose 
of 4-6 mg/day, 5-7 days before and up to 2-3 days after the 
intervention [10].
This agent may have to be continued for more than 5 
days in the case of postoperative complications, especially 
infection [98].
2.3.4. Antifi brinolytic agents (EACA [124] and tranexamic 
acid [125,126])
The dose of tranexamic acid is 1 g 4 times a day or 75 
mg/kg/day divided into 2-3 doses from 5 days before until 2 
days after surgery [125,126]. AFs are seldom used in countries 
where other treatments are available.
2.3.5. Icatibant acetate 
An isolated case of prophylaxis with icatibant acetate 
(Firazyr) prior to thyroid biopsy without local edema 
developing has been published [133]. However, controlled 
studies are necessary. The short half-life (1-2 hours) of this 
agent and the fact that it blocks B2R but does not diminish BK 
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production [33] may restrict its use in short-term prophylaxis, 
as there is a theoretical risk of late local edema. The trauma 
may result in an increase in local BK through FXII activation 
[8,134]. While B2R blockage continues, no edema is produced, 
but when B2R are released (after icatibant is eliminated from 
the body), an edema episode could develop 6-8 hours after 
surgery if BK remains high.
2.3.6. Ecallantide
One anecdotal case of short-term prophylaxis with 10 mg 
of ecallantide that did not result in edema has been reported 
[135]. However, it is worth noting that the case was a single 
uncontrolled case in which FFP was also administered. 
Moreover, the short half-life of ecallantide (2.0 ± 0.5 h) could 
restrict its use as short-term prophylaxis. It is necessary to 
carry out controlled studies or gain more experience in order 
to recommend its use in this indication. 
2.4. Peculiarities in the treatment of children and 
adolescents
2.4.1. Treatment of acute episodes
The indications are the same as in adults [98,100,114]. 
The treatment of choice is pdhC1INH [7,96,98] at 20-25 
U/kg [20,114]. If the response is insuffi cient, the dose may be 
repeated, usually an hour later [114]. 
There is no experience with icatibant acetate or ecallantide 
in children. In countries where pdhC1INH is not available, 
FFP can be used instead. The dosage has not been studied, 
although it is generally the same as that used in coagulation 
disorders (10 mL/kg) [98].
Due to the small diameter of children’s airways, mild 
edema in the laryngeal mucosa can cause a major obstruction, 
which would rapidly compromise breathing and provoke 
asphyxiation [100,136,137]. Therefore, treatment and support 
measures must be applied quickly where required. 
2.4.2. Long-term prophylaxis
The indications are the same as in adults.
AFs are the treatment of choice in children and adolescents 
(before Tanner stage V) [27], given their better safety profi le 
than that of AA [10,114]. Good control has been achieved 
with tranexamic acid at 20-40 mg/kg/day (divided into 3-4 
doses) [100,138] and with EACA at 0.17-0.43 g/kg/day [100]. 
Children had more side effects with EACA [10], leading this 
agent to fall into disuse; however, it should be considered in 
patients with lactose intolerance. The dose should be tailored 
to the minimal effective dose and adjusted for growth [10,134].
If AFs are not effective or contraindicated, they can 
be replaced with AAs. AAs have been associated with 
androgenization, premature puberty, delayed menarche, 
irregular menstruation, accelerated bone fusion resulting in 
limited growth, liver disorders, atherogenesis, and changes in 
behavior [10,87,88,139-142]. It is advisable to use the lowest 
effective maintenance dose of danazol. A dose of 2.5 mg/kg/day 
can be used, starting generally at 50 mg/day and increasing 
to a maximum of 200 mg/day if necessary [100]. Intermittent 
dosage regimens are preferred for reducing side effects (ie, 
doses repeated every other day or at 3-day intervals) [100]. 
Several cases have revealed the effectiveness and good safety 
profi le of oxandrolone in children [95]. As this agent cannot be 
aromatized to estrogen, estrogen-dependent epiphyseal bone 
closure is minimal. Oxandrolone may be more indicated for children. 
The recommended dosage is 0.1 mg/kg (2.5 to 20 mg/day) divided 
into 2 to 4 doses [94-97].
If treatment with AFs and AAs fails, regular infusions of 
pdhC1INH every 72 hours should be considered [10,26,114]. 
2.4.3 Short-term prophylaxis
The agent of choice is pdhC1INH, especially if the 
patient has a history of severe attacks precipitated by similar 
procedures, at a dose of 25 units/kg 1 hour before the procedure 
[98]. If pdhC1INH is not available, it may be replaced with 
FFP 10 mL/kg to be infused 1 hour before the procedure [98]. 
If there is enough time, AAs can be used (minimal side 
effects when used over a short period). Danazol 10 mg/kg/
day (maximum, 600 mg/day) for 5-7 days can be administered 
before and up to 2-3 days after the procedure. If androgens 
are contraindicated, tranexamic acid can be used (20-40 mg/
kg/day divided into 3-4 doses) [100, 138] during the 2 days 
before and after the procedure. This agent may have to be 
continued for more than 5 days in patients with postoperative 
complications, especially infection [98].
2.4.4  Educating patients and their families 
It is very important to educate children and their parents 
on the specifi c characteristics of the disease, potential triggers, 
how to recognize symptoms early, and the need for preventive 
treatment in special situations (eg, dental procedures). Timely 
health education and close monitoring during early childhood 
can increase the patient’s quality of life, autonomy, safety, and 
self-confi dence, as well as prevent stigmatization and provide 
a high quality of life as an adult [8].
B. Acquired Angioedema With C1 Esterase Inhibitor
    Defi ciency (AAE-C1-INH)
Control of the underlying disease generally results in 
reduced symptom severity [143,144].
Treatment of acute AE attacks is as for HAE-C1-INH, 
although the dose of pdhC1INH needed may be higher [12], 
because of the presence of anti-C1-INH autoantibodies. Clinical 
response to the infusion of pdhC1INH varies signifi cantly, 
probably as a result of varying affi nity of the autoantibodies 
for C1-INH and, consequently, of a differing rate of C1-
INH consumption [12,145]. There is little experience with 
icatibant acetate [146-148], although this agent could be used 
in cases of resistance to pdhC1INH. Ecallantide may also be 
effective, because of its mechanism of action. Antihistamines, 
corticosteroids, and adrenaline are ineffective [149].
Regarding long-term prophylaxis, there are signifi cant 
individual variations, but AFs are the treatment of choice, since 
they are more effective than AAs [143,144]. Their effectiveness 
seems to reside in their antiplasmin and plasminogen activator 
inhibitor effect [150].
Plasmapheresis followed by cyclophosphamide in a patient 
with autoantibodies against C1-INH and no underlying disease 
proved successful in 1 case [151]. The anti-CD20 monoclonal 
antibody rituximab has also been successful [152-154].
To prevent thrombotic complications in patients at risk, 
some authors recommend low-dose oral anticoagulants [12]. 
Potential prothrombotic risk factors need to be assessed 
individually.
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C.  Hereditary Angioedema Related to Estrogens (HAE
        type III) Including Hereditary Angioedema Associated
      With a Mutation in F12 (HAE-FXII)
There are no controlled studies with placebo, only case 
studies and small series. 
1. Secondary prevention: withdrawal of exogenous 
estrogens 
The main therapeutic measure is to avoid estrogens [155-
158]. In a subgroup of patients, symptoms disappear when 
situations involving increased exogenous estrogens (eg, oral 
contraceptives, hormone replacement therapy) or pregnancy 
are avoided; however, in other patients these symptoms persist, 
although milder [158,159].
ACEis should also be avoided [157], and the introduction 
of ARBs should be monitored [157].
2. Drug treatment
2.1. Treatment of acute attacks
Acute attacks do not respond to antihistamines or 
corticosteroids [157,158].
There is no consensus on treatment, with isolated cases or 
small series in which tranexamic acid (1-2 g/6 hours) [158, 
160], pdhC1INH [157,158], and icatibant acetate [158,161] 
have been used off-label. Ecallantide may also be effective 
due to its mechanism of action.
2.2. Long-term prophylaxis or maintenance therapy
In those patients in whom AE attacks do not disappear after 
withdrawing exogenous estrogens or normalizing endogenous 
estrogens, the indications for starting maintenance treatment 
are the same as in HAE-C1-INH.
There are no controlled studies with placebo. Most series 
describe the effectiveness or lack of effectiveness of various 
drugs administered empirically; therefore, all these drugs 
should be used off-label. The effectiveness of oral tranexamic 
acid [157,158,162], oral progesterone [156], and oral danazol 
[157,163] has been described. The initial dose of tranexamic acid 
is 1 g every 8 hours, which should be reduced to the minimum 
effective dose based on clinical improvement [158,162].
2.3. Short-term prophylaxis
Although no published data are available, it might be 
necessary to premedicate the patient prior to risky interventions 
in those cases where the disease continues to be active after 
avoiding estrogens or during pregnancy (see Pregnancy 
section). The therapeutic possibilities are limited (tranexamic 
acid, pdhC1INH, and icatibant acetate) and their actual 
effectiveness is unknown. If premedication is not administered, 
acute treatment should be available for immediate use.
D. Angioedema Induced by Angiotensin-Converting
    Enzyme Inhibitors (AE-ACEi)
Antihypertensives from the ACEi group should be strictly 
avoided [164].
There are few reports of AE associated with ARBs, which 
does not seem to share the same mechanism as AE-ACEi 
[165-167]. A low percentage of patients with AE-ACEi 
develop AE when the ACEi is replaced by an ARB [164,166]. 
However, in a recent meta-analysis, the prevalence of ARB-
induced AE in patients with AE-ACEi was 1.5% (95% 
CI, 0%-5.1%), with no signifi cant difference with placebo 
[168,169]. Therefore, ARBs should not be systematically 
avoided in patients with AE-ACEi, although their use should 
be monitored.
AE episodes that occur during treatment with ACEi do 
not respond to treatment with antihistamines, corticosteroids, 
or adrenaline [170]. Tranexamic acid may be effective, just 
as with other types of BK-AE [162,171]. The effectiveness 
of pdhC1INH has been described in 1 case [172] and that 
of icatibant acetate in a recently published series [170,173], 
although more studies are needed to confi rm this benefi cial 
effect.
 
Follow-up
The frequency of follow-up visits and the type of 
complementary examinations depend on the intensity and 
frequency of symptoms, as well as the type of treatment 
received (Table 11). 
At diagnosis and before starting treatment, biochemical 
and serological analysis and abdominal ultrasound should 
be performed [8-10,27,174,175].
In patients on long-term prophylaxis with AAs, follow-
up should preferably be every 6 months. A physical 
examination is necessary to look for signs of virilization 
and to monitor weight and blood pressure. Analytical checks 
should also be carried out, including a complete blood count, 
lipid profi le, liver function tests (alanine aminotransferase, 
aspartate aminotransferase, alkaline phosphatase), and 
elementary urinalysis [8-10,27,82,174,175]. An annual 
measurement of α-fetoprotein is also recommended [9]. 
In order to make an early diagnosis of possible liver 
adenomas, abdominal ultrasound should be performed 
at baseline and at least every year and every 6 months if 
the dose exceeds 200 mg/day of danazol or 2 mg/day of 
stanozolol and with any dose if the patient has been treated 
for more than 10 years with AAs [7-10,27,174-176]. Patients 
undergoing prophylactic antifi brinolytic treatment should 
receive serum muscle enzyme and undergo liver function 
testing every year, as well as ophthalmologic examinations 
[9,10,177]. Thrombosis has been reported in patients with 
hypercoagulable states [178]; therefore, it is advisable to 
perform a hypercoagulability study prior to administration 
in patients with a family history of thrombophilia or active 
thromboembolic disease.
Due to the potential theoretical risk of transmission of 
infectious agents, serology testing should be performed for 
HCV, HBV, HIV, and parvovirus B19 [10,22,23,174,179,180].
Persons with C1-INH defi ciency should be considered 
patients, even if they are asymptomatic, and actively 
monitored.
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Table 11. Follow-up and Complementary Testsa 
 
 Treatment Baseline Visit 6-Month Visit Annual Visit 
Androgen • Abdominal ultrasound • Physical examination: • α-Fetoprotein
 • Hemogram    – Virilization signs • Abdominal ultrasound
 • Liver function tests    – Weight 
 • Lipid profi le    – Blood pressure
 • Urinalysis • Hemogram
  • Liver function tests
  • Lipid profi le
  • Urinalysis
  • Abdominal ultrasoundb
Antifi brinolytic agents Hypercoagulability studyc • Muscle enzyme testing • Ophthalmology checkup
     (aldolase, creatine
     phosphokinase)
  • Liver and renal function
  • Urinalysis
pdhC1INH  Serological test:  Serology testingd
(hemovigilance required) • HCV  • HCV
 • HBV  • HBV
 • HIV  • HIV
 • Parvovirus B19  • Parvovirus B19
 Vaccination hepatitis B
aMonitoring varies according to long-term prophylaxis (androgens vs antifi brinolytics); hemovigilance should be performed in all
 patients because of pdhC1INH treatment.
bIn patients treated for  >10 years or receiving >200 mg/day danazol or 2 mg/day stanozolol or prepuberal patients.
cIn patients with family history of thrombophilia or active thromboembolic disease.
dIn cases where the patient has received pdhC1INH since the last visit.
Special Situations
Contraception
Contraceptives that contain estrogens are contraindicated 
in patients with HAE-C1-INH and HAE type III (including 
HAE-FXII), given that these drugs can produce an increase in 
the frequency and severity of AE episodes [99,155-157,181]. 
As an alternative, patients can use continuous low doses of 
oral progestogen (mini-pill), such as desogestrel, norgestrel, 
levonorgestrel, lynestrenol, and ethynodiol diacetate. One 
retrospective study revealed that 64.3% of women with HAE-
C1-INH who took progestogens as contraceptives improved 
during the course of their AE [155]. In Spain, the only marketed 
oral progestogen for contraceptive use is desogestrel (Cerazet, 
Schering-Plough, Madrid, Spain).
As for the intrauterine device (IUD), there is little published 
data on its safety. However, one European retrospective study 
showed good tolerance [155]. No short-term prophylaxis 
is needed for insertion, although acute treatment should be 
available. There is an IUD with progesterone (levonorgestrel-
releasing IUD: Mirena, Bayer, Barcelona, Spain), which could 
be specifi cally indicated for patients with HAE-C1-INH. 
Finally, condoms and other barrier methods are an 
alternative with no contraindications.
As for emergency contraceptives (morning after pill), 
there is no theoretical risk of worsening as long as the patient 
uses only those with high doses of progestogens. If the patient 
uses those with high doses of estrogens, acute treatment must 
be on hand in case of exacerbations. Another alternative is 
implantation of an emergency IUD within the fi rst 72 hours 
[182]. 
Secure contraception must be ensured when the patient is 
being treated with androgens, which carry a high teratogenic 
risk.
Pregnancy and Childbirth
• Pregnancy and HAE-C1-INH and HAE type III
Pregnancy may improve, worsen, or have no impact on 
the course of HAE-C1-INH attacks, which may vary from one 
pregnancy to another in the same patient [78,155,183-188].
Pregnancy is one of the known exacerbating factors in 
HAE type III [157,160,163,189,190].
• C1-INH levels during pregnancy
HAE-C1-INH should not be diagnosed during pregnancy, 
since transient low levels of C1-INH have been reported in 
women with or without HAE-C1-INH, although these levels 
return to normal values after delivery [191-193]. This could 
be associated with increased circulating plasma volume [194].
• Scheduled pregnancy
Androgens should be discontinued before pregnancy, since 
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they can cross the placental barrier and produce virilization 
of the fetus, in turn leading to female pseudohermaphroditism 
[195-198].
Since the elimination half-life of danazol is 9.44±2.74 
hours [199], avoidance of danazol 1 month prior to conception 
should be suffi cient.
If the pregnancy test is positive, androgen treatment should 
be discontinued immediately.
Although tranexamic acid also crosses the placental barrier 
[200], there are no known signifi cant side effects for the fetus; 
therefore, this treatment can be continued, bearing in mind its 
controversial prothrombotic effects.
 The half-life of tranexamic acid is approximately 2 hours 
[201]; therefore, discontinuing its use a few days before 
conception is suffi cient.
Ecallantide, icatibant acetate, and rhC1INH have not 
been used during pregnancy and should be avoided before 
conception. As their half-lives are short, avoiding them a few 
days before conception is suffi cient.
pdhC1INH should not be avoided prior to conception.
• Treatment of HAE-C1-INH during pregnancy
The treatment of choice for AE attacks during pregnancy is 
pdhC1INH (20 U/kg) [186,188]. Icatibant acetate, ecallantide, 
and rhC1INH have not been used in pregnancy, and their safety 
profi le is unknown.
As for short-term prophylaxis, pdhC1INH is also preferred 
over other options.
Regarding long-term prophylaxis, the use of androgens is 
contraindicated throughout pregnancy, due to their virilizing 
effects on the fetus [197,198]. There are no controlled data on 
the use of AFs during pregnancy, and there is no consensus 
on the need to monitor other prothrombotic factors. In studies 
of pregnant women with hemorrhaging, coagulation was 
not signifi cantly affected [202-204]. However, if the patient 
has a family or medical history of prothrombotic events, 
then AFs should be administered with caution, and a prior 
hypercoagulability study should be performed.
There are few controlled data on the use of pdhC1INH 
during pregnancy, although most experts have extensive 
experience with this agent. Several series have recently been 
published on the effi cacy and safety of pdhC1INH in pregnancy 
[186,188,205].
• Treatment of AEH type III during pregnancy
Currently, there are no clear therapeutic alternatives to 
pdhC1INH, although successful isolated experiences have 
been reported with tranexamic acid and pdhC1INH [158]. 
As there is no experience with icatibant acetate or ecallantide 
during pregnancy, these agents are not recommended, except 
under life-threatening AE attacks that do not respond to other 
treatments.
Regarding short-term prophylaxis, it might be necessary 
to premedicate the patient with pdhC1INH or tranexamic acid 
prior to risky interventions during pregnancy, although the 
real effectiveness of these agents is unknown. Acute treatment 
should be available.
• Childbirth (HAE-C1INH)
Although a signifi cant trauma, childbirth has not been 
shown to be a trigger for AE. It is generally well tolerated 
without prior prophylaxis with pdhC1INH [155]. However, 
in recent years, a signifi cant bias has been generated with 
the publication of isolated cases in which pdhC1INH was 
administered as prophylaxis [206-210]. Nevertheless, larger 
series show that spontaneous vaginal deliveries tend to be 
well tolerated [188]. Therefore, an observational approach 
should be adopted with this type of delivery, and at least 1 
dose of pdhC1INH (20 U/kg) should be kept in the delivery 
room. For complicated childbirths that require vacuum or 
forceps, prior administration of purifi ed plasma pdhC1INH is 
recommended. In patients with no control of the disease and 
frequent acute outbreaks, prophylactic pdhC1INH should 
be administered before delivery. The dose can be adjusted 
according to the patient’s weight (50 kg, 500 U; 50-100 kg, 
1000 U; >100 kg, 1500 U). The patient should be closely 
monitored during the postpartum, in case complications 
arise [208,209,211].
If a cesarean section is required, local anesthesia is 
preferable in order to avoid the risk of laryngeal edema 
secondary to endotracheal intubation. pdhC1INH (500-1500 U) 
must be administered prior to the procedure, with a treatment 
dose (20 U/kg) on hand in case of complications.
• Childbirth (HAE type III)
For patients with HAE type III, delivery may pose a risk 
of AE; therefore, some authors recommend administering 
pdhC1INH prior to delivery [158]. Acute treatment should be 
available for immediate use.
• Genetic counseling
Adult patients and/or their family must be informed of 
the possibility of transmitting HAE-C1-INH and HAE-FXII 
to offspring. They should also be informed about available 
treatments and the fact that it is impossible to predict severity 
in offspring. When permitted by law, the patient should be 
informed of the possibility of performing prenatal diagnosis 
or in vitro fertilization with preimplantation genetic diagnosis 
and selection of healthy embryos. Preimplantation genetic 
diagnosis is a complicated technique with a low success rate. 
This approach is more complicated in women with HAE-C1-
INH or HAE-FXII, since it can worsen AE through estrogenic 
stimulation during in vitro fertilization techniques.
Organ Donation and Blood Transfusion
HAE-C1-INH is a genetic disease caused by a defi ciency 
or alteration in the function of C1-INH. This protein is 
synthesized and expressed mainly in the liver (http://biogps.
gnf.org/ Accessed November 19, 2010). For this reason, 
patients with HAE-C1-INH can donate all of their organs 
except the liver [212].
However, according to exclusion criteria for blood and 
blood component donors in Royal Decree 1088/2005, patients 
with HAE-C1-INH and HAE-FXII may not donate blood 
[213].
Advice to Patients Before Traveling
Long-term prophylactic treatment should be adjusted. A 
written medical report may be necessary for the medication to 
pass airport security. The report must detail the characteristics 
of the disease and the pertinent instructions for emergency 
treatment or short-term prophylaxis. 
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Both pdhC1INH and icatibant acetate must be declared 
at the check-in desk and carried by hand in a refrigerated 
bag (only if temperatures are expected to be above 25ºC). 
Patients should be advised to carry the materials needed for 
administration of the medication (a syringe and a needle for 
intravenous administration of pdhC1INH) in case they suffer an 
attack and have no access to a health center where medication 
can be administered. 
Patients are recommended to carry a card that identifi es this 
disease and its treatment. The Spanish Association of Family 
Angioedema (AEDAF) has a card written in 4 languages for 
this very purpose.
AEDAF’s website (http://www.angioedema-aedaf.org) 
provides extensive information on the Spanish hospitals and 
health centers that are familiar with this disease and have 
emergency treatment available. It may also be useful for 
patients to consult the websites of the patient associations of 
the various countries they intend to travel to.
Other Situations
Coordination With Primary Care 
Liaising closely with the patient’s primary care physician 
is recommended. Telephone or email contacts for the unit that 
cares for the patient should be provided.
Patient Booklet
The patients and their family should have access to a simple 
publication that provides basic relevant information on self-
care and monitoring.
Personal Availability of Acute Treatment
Based on current information, patients at risk of life-
threatening outbreaks must have personal access to acute 
treatment. The health care system should provide patients with 
pdhC1INH or icatibant acetate and their replacement once 
these drugs have been used up or have expired.
Patient Associations
Patients and their families should be provided with the 
means to contact patient associations or social organizations 
for support (http://www.angioedema-aedaf.org).
Disease Records
Considering the rarity of this type of disorder, a disease 
registry can be useful, bearing in mind the confi dentiality issues 
outlined by Spanish legislation.
Individualized Clinical Report
Every patient with BK-AE should have a clinical report, 
especially when the diagnosis is made. At least every 2 years, 
the report should be revised to include the latest details on the 
patient’s condition.
It may be useful to have a “rapid medical alert” in the form of 
a bracelet/necklace or electronic device that contains information 
on diagnosis, emergency treatment, and ineffectiveness of drugs 
(antihistamines, corticosteroids, and adrenaline).
Document Review
This Consensus Document should be reviewed before 
January 2013 by the corresponding SEAIC Study Group.
 The fi nal version has been read and approved by all the 
authors.
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